Single Domain Biotherapeutics
Humanised single domains for direct therapeutics and targeted delivery.
LlamdA® & VHHantage Antibodies
LlamdA® and VHHantage VHH are humanised monovalent antibodies.
Small in size (15 kD), biophysically robust and with tunable half-lives these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery.
LlamdA® is Isogenica’s proprietary fully synthetic single domain VHH library, built with our precision COLIBRA® technology to eliminate liabilities and provide biophysically robust therapeutic antibodies. The VHHantage library also offers greater diversity, less liabilities and more developable humanised VHH antibodies.
Isogenica ISOXTEND® half-life extension for biotherapeutics
Our VHH-based ISOXTEND® technology protects biotherapeutics from kidney clearance by ‘piggybacking’ onto the serum albumin endocytic recycling pathway, significantly extending therapeutic half-life.
What are
VHH?
In the early 1990’s researchers discovered that camels and llamas produce heavy-chain only antibodies.
Their small size, high stability and full antigen binding capacity identified them as potentially excellent building blocks for novel non- IgG biotherapeutics.
In 2019 the first VHH biotherapy received FDA approval. Originally discovered and developed by Ablynx, Caplacizumab gained regulatory approval in February 2019. New approvals are expected imminently with a significant and growing pipeline of VHH therapeutics in clinical development.
VHH Features
